Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says
Morgan Stanley analysts upgraded shares of Biogen and downgraded shares of Celgene over concerns of generic drug pressures. TheStreet's Jim Cramer called these moves "useless."
Biogen (BIIB) - Get Report was upgraded to overweight from equal weight by Morgan Stanley analysts on Thursday, while Celgene (CELG) - Get Report was downgraded to underweight from equal weight by Morgan Stanley.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer called these moves "useless."
"It's just kind of a shuffling," Cramer said.
Watch all of Jim Cramer's latest videos, right here:
- Amazon's Potential Delivery Service Not a Reason to Sell FedEx, UPS: Jim Cramer
- Jim Cramer Isn't Happy With His New HP Laptop
- Jim Cramer on Bill Ackman: Give Him an ADP Board Seat
